Linda and friend
Somewhere in northern Mexico
A long time ago
Here is
another example of the unholy (or at least peculiar) alliance between Biotech
and Wall Street.
A tiny (3
person!) outfit out of San Jose, CA, has just announced a European patent on
what sounds to me like a damned good anti-OVCA vaccine. The outfit is called Anixa Biosciences; stock
market symbol ANIX, currently going at $5.40/share. As far as I can see, Anixa has never made a
profit – at least not in the last four years – and appears to not have had any revenue
in 2020! Do not regard this as a
stock-marketing tip!
But Anixa,
in company with several dudes from something called the Cleveland Clinic, has
produced and is attempting to market what appears to me to be a most valuable contribution to the task of
ridding the world of ovarian cancer. It
appears that there is a protein (with a ponderous name – see the link below)
that is expressed in the ovaries of pre-menopausal women. With menopause it goes away. However, with the onset of OVCA it comes back
and contributes to caner growth (I think).
Anyway, these San Jose/Cleveland people have developed a vaccine, to be
administered to post-menopausal females.
This vaccine induces the immune system to destroy the unnecessary and unwanted
protein, apparently thus inhibiting cancer growth. At least, that’s what I make of it. Here, read it for yourself:
No comments:
Post a Comment